Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.83% | 1,155.61% | -6.54% | -5.37% | -23.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.83% | 1,155.61% | -6.54% | -5.37% | -23.47% |
| Cost of Revenue | 14.33% | 248.42% | 136.56% | -5.05% | -33.38% |
| Gross Profit | -22.63% | 207.14% | -94.40% | -5.55% | -16.93% |
| SG&A Expenses | -14.37% | 172.65% | -23.02% | -16.39% | -44.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.41% | 211.24% | 31.57% | -12.88% | -37.54% |
| Operating Income | -71.02% | -100.40% | -259.75% | 104.43% | 80.04% |
| Income Before Tax | -102.25% | -99.85% | -292.26% | 124.63% | 84.08% |
| Income Tax Expenses | 106.98% | -72.11% | 598.27% | 356.53% | 102.58% |
| Earnings from Continuing Operations | -102.35% | -115.32% | -354.96% | 96.79% | 81.10% |
| Earnings from Discontinued Operations | 64.23% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.95% | 65.29% | -354.96% | 96.79% | 56.39% |
| EBIT | -71.02% | -100.40% | -259.75% | 104.43% | 80.04% |
| EBITDA | -509.05% | -92.62% | -571.63% | 2,839.51% | 95.09% |
| EPS Basic | -10.97% | 65.11% | -350.90% | 96.84% | 56.52% |
| Normalized Basic EPS | -108.00% | -97.44% | -286.04% | 124.35% | 84.13% |
| EPS Diluted | -12.02% | 65.11% | -351.11% | 94.74% | 56.75% |
| Normalized Diluted EPS | -108.00% | -97.45% | -286.04% | 124.35% | 84.13% |
| Average Basic Shares Outstanding | -2.73% | -0.54% | 0.91% | 1.03% | 0.31% |
| Average Diluted Shares Outstanding | -2.73% | -0.22% | 0.91% | 1.03% | 0.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |